middle.news
Imricor Advances US Market Bid with Form 10 Amendment and FDA Clearances
9:06am on Monday 27th of April, 2026 AEST
•
Healthcare
Read Story
Imricor Advances US Market Bid with Form 10 Amendment and FDA Clearances
9:06am on Monday 27th of April, 2026 AEST
Key Points
Form 10 amendment addresses SEC review comments, effective May 17, 2026
FDA 510(k) clearance secured for NorthStar Mapping System and Vision-MR Diagnostic Catheter
VISABL-AFL and VISABL-VT trials ongoing to support US approval expansion
2025 revenue slumps 70% to $292K, net loss narrows to $25.3M
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Imricor Medical Systems (ASX:IMR)
OPEN ARTICLE